ALS - Overview and PT Management Flashcards

1
Q

ALS definition

A

Amyotrophic lateral sclerosis (ALS) is a progressive
neurodegenerative disease characterized by
degeneration and eventual death of upper motor neurons and lower motor neurons causing weakness of the limb, respiratory, and bulbar musculature.

  • MOST COMMON MN DISEASE IN ADULTS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Meaning of amyotrophy

A

muscle wasting

-loss of brains, CN nuclei and anterior horn cells in spinal cord

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

meaning of lateral sclerosis

A

hardening of the lateral spinal cord due to gliosis of pyramidal tracts

-loss of cortical motor cells causing corticospinal tract dysfunction –> affect on voluntary movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Epidemiology of ALS

A

more common in men 1.7:1

peak age of diagnosis: 65-70

median onset: 51-66 years

** usually diagnosed after 40 years old

more prevalent in white persons compared to non-white (might be methodological issues)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Risk Factors ALS

A

-older age
-lower BMI
-cigarette smoking
-professional athletes are more at risk than recreational athletes
-repeated head injuries
-exposure to toxic chemicals

-5-10% cases are familial –> 30 ALS associated genes identified

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pathology of ALS

A

-dysfunction of astrocytic excitatory amino acid transporter 2 (EAAT 2)

-glutamate excitotoxicity due to reduced uptake of glutamate from synaptic cleft –> leads to neurodegeneration through activation of Ca dependent enzymatic pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is excitotoxicity?

A

Excitotoxicity is a phenomenon that describes the toxic actions of excitatory neurotransmitters, primarily glutamate, where the exacerbated or prolonged activation of glutamate receptors starts a cascade of neurotoxicity that ultimately leads to the loss of neuronal function and cell death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the name of the criteria that helps to clinically diagnose ALS?

A

EL ESCORIAL CRITERIA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

3 findings for Clinical Diagnosis ALS:

A

1- Evidence of LMN degeneration by
clinical, electrophysiological (EMG)
or neuropathological exam

2- Evidence of UMN degeneration by
clinical exam

3- Progression within a body region and two other regions

** THREE REGIONS TOTAL NEED TO BE AFFECTED

DEFINITE ALS:
-presence of UMN and LMN signs in 3 anatomical regions

PROBABLE ALS:
-presence of UMN and LMN signs in at least two regions with UMN sign rostral to LMN signs

PROBABLE ALS, lab results supported:
-presence of UMN and LMN signs in one region with evidence by EMG of LMN involvement in another region

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

UMN AND LMN SIGNS IN ALS

A

UMN SIGNS
-weakness
-spasticity
-hyperrefelxia
-pathologic reflexes
-pseudobulbar affect –> crying or laughing uncontrollably

LMN SIGNS
-weakness
-muscle wasting
-muscle cramps
-fasciculations–> involuntary muscle twitching

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Spectrum of ALS

A

MOST COMMON: bulbar and spinal onset ALS

SPINAL ONSET
-fasciculations, atrophy, weakness, spasticity
-affects the limbs

BULBAR ONSET
-changes in speech, diff swallowing, involuntary tongue twitching
-more common in women > 60
-typically progresses faster

RESPIRATORY ONSET - RARE: ~1%
-SOB
-orthopnea –> SOB in supine/prone
-sleep disordered breathing

-cognitive impairment in 50% of the patients
–> changes in behavior (disinhibition, lack of judgement, apathy)
-difficulty with expression of language but comprehension preserved
-executive dysfunction
-15% meet criteria for frontotemporal dementia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Patient typically decline _____ point/month on the ALS functional rating scale

A
  • most widely used measure of disability progression for ppl with ALS

1 point per month

12 points possible in each category

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ALSFRS-R MEANING

A

ALS functional rating scale- revised

used to measure disability progression in ALS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ALSFRS-R MEANING

A

ALS functional rating scale- revised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ALSFRS-R categories

A

BULBAR
-speech
-salivation
-swallowing

FINE MOTOR
-handwriting
-cutting food
-dressing and hygiene

GROSS MOTOR
-turning in bed
-walking
-climbing stairs

RESPIRATORY
-dyspnea
-orthopnea –> progress to using more pillows or sleep sitting up–> unable to sleep
-respiratory insufficiency –> use of bipod or mechanical ventilation most extreme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

King’s clinical staging of ALS

A

presymptomatic
involvement of one clinical region
involvement of two clinical regions
involvement of three
substantial or respiratory or nutritional failure
death

17
Q

MITOS functional staging of ALS

A

functional involvement (disease onset)

loss of independence in one functional domain

loss of independence in two

loss of independence in three

loss of independence in four

death

18
Q

Prognosis

A

-death typically 2-5 years after disease onset

-10 year survival: 10%

NEG FACTORS:
-bulbar onset
-weight loss
-cog impairment
-impaired respiratory function

PT : maintaining function for longer periods, decreasing caregiver burden, facilitating referrals, expediting equipment

19
Q

Assessments of motor function

A

MMT, MVIC (maximum voluntary isometric contraction), dynamometer (quantify loss of mm. over time)

respiratory function - FVC (forced vital capacity), max inspiratory force (MIF)

20
Q

Quality of life scales for ALS

A

SF-36

ALS assessment questionnaire (ALSAQ-40

21
Q

Two common medications used for ALS

A

Rilutek, Tiglutik (riluzole)

Radicava (edaravone)

22
Q

Access to medical aid in dying —>

A

may be available in certain states

23
Q

Commonly reported symptoms

A

fatigue
muscle stiffness
muscle cramps
SOB
difficulty sleeping
pain
anxiety
depression

24
Q

Body structure and function

A

ROM
strength –> muscle wasting very common
sensation
muscle tone
skin integrity
cognition–> ALS cognitive behavioral scale

-respiratory status - breathing pattern, chest auscultation, respiratory rate, cough strength

25
Q

Measures for activity limitations:

A

Gait
-10MWT
-2/6MWT

Balance
-Berg
-TUG
-Function in sitting test

26
Q

Measures for activity limitations:

A

Gait
-10MWT
-2/6MWT

Balance
-Berg
-TUG
-Function in sitting test

27
Q

Participation outcome measures

A

ALSSQOL-R: The ALS Specific Quality of Life-Revised

Patient Specific Functional Scale - salient activities for pt

28
Q

EXAMPLE GOALS FOR POC

A
  • Patient/caregiver independence in a range of motion, stretching, or
    exercise program. (Focus on function and QoL)
  • Patient/caregiver independence in functional mobility.
  • Patient and/or family training in use of specialized equipment.
  • Patient and/or family understanding of safety awareness measures and
    strategies for preventing complications.
  • Reduction/elimination of pain or discomfort and/or joint limitations.
    • ALMOST ALL ARE COMPENSATORY
29
Q

Multidisciplinary management

A

SLP
-augmentative devices
-speech gen strategies/devices
RD- swallowing and nutrition- percutaneous endoscopic gastronomy - feeding tube through abdominal wall and into the stomach

respiratory function

psychological issues

ADLs

30
Q

Approach to PT intervention in ALS

A

-interventions vary based on early, middle, or late stage of disease

Focus on prevention and compensation more than remediation

PREVENTION:
-ex: manual w/c can prevent fall and conserve energy

COMPENSATION
-ex: AFO for drop foot, button hook

REMEDIATION
-recovering function from sequalae of disease, not the disease itself –> adapting ADLs, providing strategies

31
Q

Interventions for fatigue

A

prevention/
compensation:
-energy conservation techniques
-ADs, ADL equipment, braces

rehab/remediation
-aerobic ex? (reduce secondary consequences)

32
Q

Interventions for weakness

A

prevention/
compensation:
-mobility equip, home modifications
-orthotics
-adaptive equipment (reachers, long handles, feeding aids

rehab/remediation:
-only at mild-mod intensity for muscles that CAN move against gravity

33
Q

Can you improve the weakness affected by ALS?

A

NO

34
Q

Interventions for pain

A

prevention/
compensation:
-orthotics, positioning equipment
-transfer training, pressure relief, ROM
-shoulder sling to prevent pain associated with shoulder subluxation/muscle weakness

rehab/remediation:
-ROM, STM, joint mobilization modalities

35
Q

Interventions for spasticity/stiffness

A

prevention/
compenstion:
-braces/splints (compensation)

-stretching, ROM (prevention)

rehab/remediation:
-weightbearing, light res. ex.

36
Q

Potential harms of exercise in those with ALS and competing evidence

A

-may inc. sx of fatigue and weakness (short term)
-IF NOT DOSED CORRECTLY–> could facilitate overuse of motor units and disease progression (long term)

** could be beneficial if dosing is correct

Exercise can improve functional ability & pulmonary function in people with ALS (compared to no exercise or usual care)
- DO NOT target muscles that can’t move against gravity
-can also target unaffected muscles
-probably better early in the disease course
-be careful not to fatigue them too much-

37
Q

Recommended MODE of exercise for ppl with ALS?

A
  • Endurance/aerobic exercise (mild intensity: 55-60% HR max) better
    than resistance exercise in improving functional ability
  • Flexibility exercise is safe and beneficial

-low intensity is best

-early in disease process is best